Preparation and evaluation of floating risedronate sodium-gelucire® 43/01 formulations

Drug Development and Industrial Pharmacy

Volumn 31, Issue 9, 2005, Pages 851-860

  Chauhan, Bhaskar ^a   Shimpi, Shyam ^a   Mahadik, K R ^a   Paradkar, Anant ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Drug release; Floating; Gelucire; Hot stage microscopy; Multi unit; Risedronate sodium; Single unit

Indexed keywords

GELUCIRE; RISEDRONIC ACID;

AGING; ARTICLE; CONTROLLED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG GRANULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; SCALE UP; SCANNING ELECTRON MICROSCOPY; SOLID STATE; TABLET MATRIX;

BONE DENSITY CONSERVATION AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; ETIDRONIC ACID; EXCIPIENTS; MICROSCOPY, ELECTRON, SCANNING; RADIONUCLIDE IMAGING; THERMODYNAMICS; TRIGLYCERIDES;

EID: 27544516370     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500271837     Document Type: Article

References (28)

1. Ahlgren, N., Cascone, J., Fitzpatrick, J., Frisbee, S. E., Getz, J., Herman, M. R., Kiernan, B. M., Barbara, O. E., Pereira, D., & Sanghvi, P. P. (12 September, 2000). Fatty Ester Combinations. U.S. Patent 6,117,452.
2. Aïnaoui, A., & Vergnaud, J. M. (1998). Modelling the plasma drug level with oral controlled release forms with lipidic gelucire. International Journal of Pharmaceutics, 169, 155-162.
3. Aïnaoui, A., Ouriemchi, E. M., Bidah, D., El Amrani, M. K., & Vergnaud, J. M. (1997). Process of drug release with oral dosage forms with lipidic gelucire matrix. Journal of Polymer Engineering, 17, 245-257.
4. Barker, S. A., Yap, S. P., Yuen, K. H., McCoy, C. P., Murphy, J. R., & Craig, D. Q. M. (2003). An investigation into the structure and bioavailiability of α-tocopherol dispersion in Gelucire 44/14. Journal of Controlled Release, 91, 477-488.
5. Boulenc, X., Breul, T., Gautier, J. C., Saudemon, P., Joyeux, H., Roques, C., Berger, Y., & Fabre, G. (1995). Sodium lauryl sulphate increases tiludronate paracellular transport using epithelial Caco-2 monolayers. International Journal of Pharmaceutics, 123, 71-83.
6. Bowtle, W. (2000). Lipid formulations for oral drug delivery. Pharmaceutical Technology Europe, 12, 20-30.
7. DeGroen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillostson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1999). Esophagitis associated with the use of alendronate. New England Journal of Medicine, 335, 1016-1021.
8. Delmas, P. D., & Meunier, P. J. (1997). The management of Paget's disease of bone. New England Journal of Medicine, 336, 558-556.
9. Dennis, A. B., Farr, S. J., Kellaway, I. W., Taylor, G., & Davidson, R. (1990). In vivo evaluation of rapid release and sustained release gelucire capsule formulations. International Journal of Pharmaceutics, 65, 85-100.
10. Flashner-Barak, M., Rosenberger, V., Dahan, M., & Lerner, Y. (3 January, 2002). Composition and Dosage Form for Delayed Gastric Release of Alendronate and/or Other Bisphosphonates. WO 2002000204.
11. Fleisch, H. (1997). Bisphosphonates: preclinical aspects and use in osteoporosis. Annals of Medicine, 29, 55-62.
12. Gert, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., Freeman, A., Quan, H., Lasseter, K. C., Mucklow, J. C., & Porras, A. G. (1995). Studies of the oral bioavailablity of alendronate. Clinical Pharmacology & Therapeutics, 58, 288-298.
13. Green, J. R., Clay, V., Richardson, J., & Hassan, I. F. (1997). The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo. International Journal of Pharmaceutics, 153, 59-66.
14. Iannuccelli, V., Coppi, G., Bernabei, M. T., & Cameroni, R. (1998). Air comparment multiple-unit system for prolonged gastric residence. Part I. Formulation study. International Journal of Pharmaceutics, 174, 47-54.
15. Johansen, A., Stone, M., & Rawlinson, F. (1996). Bisphosphonates and the treatment of bone disease in the elderly. Drugs and Aging, 8, 113-126.
16. Kumar, K., Shah, M. H., Ketkar, A., Mahadik, K. R., & Paradkar, A. (2004). Effect of drug solubility and different excipients on floating behavior and release from glyceryl mono-oleate matrices. International Journal of Pharmaceutics, 272, 151-160.
17. Lin, J. H. (1996). Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18, 75-85.
18. Lindmark, T., Kimura, Y., & Artursson, P. (1998). Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. Journal of Pharmacology and Experimental Therapeutics, 284, 362-369.
19. Lufkin, E. G., Argueta, R., Whitaker, M. D., Cameron, A. L., Wong, V. H., Egan, K. S., O'Fallon, W. M., & Riggs, B. L. (1994). Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis International, 4, 320-322.
20. Niemi, R., Vepsalainen, J., Taipale, H., & Jarvinen, T. (1999). Bisphonates prodrugs: synthesis and an in vitro evaluation of novel acyloxylated esters of clodronic acid. Journal of Medicinal Chemistry, 42, 5053-5085.
21. Niemi, R., Vepsalainen, J., Taipale, H., & Jarvinen, T. (2000). Bisphonates prodrugs: synthesis and in vitro evaluation of alkyl and acyloxy esters of etidronic acid as bioreversible prodrugs of etidronate. European Journal of Pharmaceutical Sciences, 11, 173-180.
22. Porter, C. J. H., & Charman, W. N. (2001). In vitro assessment of oral lipid based formulations. Advanced Drug Delivery Reviews, 50, S127-S147.
23. Pouton, C. W. (1985). Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification. International Journal of Pharmaceutics, 27, 335-348.
24. Raiman, J., Tormalehto, S., Yritys, K., Junginger, H. E., & Monkkonen, J. (2003). Effect of various absorption enhancerson transport of clodronate through Caco-2 cells. International Journal of Pharmaceutics, 261, 129-136.
25. Sheu, M. T., Hsia, A., & Ho, H. O. (2001). Polyglycolized saturated glycerides as carrier and enhancer for drug penetration. Chinese Pharmaceutical Journal, 53, 107-111.
26. Sutananta, W., Craig, D. Q. M., & Newton, J. M. (1994). The effects of ageing on the thermal behaviour and mechanical properties of pharmaceutical glycerides. International Journal of Pharmaceutics, 111, 51-62.
27. Sutananta, W., Craig, D. Q. M., & Newton, J. M. (1995). An evaluation of the mechanisms of drug release from glycerides bases. Journal of Pharmacy and Pharmacology, 47, 182-187.
28. Twiss, I. M., De Water, R., Den Hartigh, J., Sparidans, R., Ramp-Koopmanschap, W., Brill, H., Wijdeveld, M., & Vermeij, P. (1994). Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. Journal of Pharmaceutical Sciences, 83, 699-703.